{"id":77189,"date":"2022-04-01T10:00:00","date_gmt":"2022-04-01T09:00:00","guid":{"rendered":"http:\/\/histocell.com\/iteas\/"},"modified":"2023-02-24T14:12:13","modified_gmt":"2023-02-24T13:12:13","slug":"iteas","status":"publish","type":"post","link":"https:\/\/histocell.com\/en\/iteas\/","title":{"rendered":"ITEAS"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
CURRENT PROJECTS<\/span><\/h5>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

<\/span>ITEAS<\/span><\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

April<\/strong> 2022- December 2024<\/span><\/p>\n

Reference no: ZE-2022\/00021<\/span><\/p>\n

Call: HAZITEK ESTRATEGICO 2022<\/span><\/p>\n

Project co-financed by the Basque Government and FEDER funds, under the HAZITEK business R&D support programme.<\/p>\n

\u201cInvestigaci\u00f3n en TErapias AvanzadaS para la resoluci\u00f3n de necesidades m\u00e9dicas no resueltas\u201d<\/span><\/em><\/p>\n

The overall objective of the ITEAS consortium, led by HISTOCELL S.L., and involving 9 other companies, is to establish a sustainable Basque ecosystem that overcomes the technological and regulatory obstacles for the implementation of an industry based on Advanced Therapies.<\/p>\n

To achieve this objective, the ITEAS consortium proposes research in the development of drugs for cell therapy (HISTOCELL), tissue therapy (UNIKARE, TECBIOCEL), and combined (POLIMERBIO, EKOLBER, UNIKARE, TECBIOCEL), and in their regulatory (TECNALIA CERTIFICATION); as well as in two key research lines complementary to the development of advanced therapy drugs; one is additive manufacturing as a manufacturing method for advanced therapies combined with biomaterials (DOMOTEK); and the second is diagnostics for therapeutic purposes (companion diagnostics) (GRAPHENEA, MEPRO, IMG PHARMA). The combination of drugs for advanced therapies, 3D printing techniques and diagnostic systems form the basis of personalised medicine.<\/p>\n

Histocell participates as leader of the project, with the aim of achieving a deep understanding of the development processes of biological drugs based on mesenchymal stem cell exosomes from adipose tissue, as a future alternative to the use of stem cells as a cell therapy drug. During the project, two new processes will be developed: a reproducible and validable process for the isolation and concentration of exosomes from MSCs, which will allow the development of a manufacturing protocol for exosomes for clinical use in patients, which can then be scaled up to HISTOCELL’s manufacturing plant under GMP conditions; and a galenic formulation of exosomes obtained from MSCs in a reconstitutable powder, stable and easy to transport and store, for subsequent application to the patient under optimal conditions.<\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"logo-gobierno-vasco\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"logo-feder\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

CURRENT PROJECTS ITEAS April 2022- December 2024 Reference no: ZE-2022\/00021 Call: HAZITEK ESTRATEGICO 2022 Project co-financed by the Basque Government and FEDER funds, under the HAZITEK business R&D support programme. \u201cInvestigaci\u00f3n en TErapias AvanzadaS para la resoluci\u00f3n de necesidades m\u00e9dicas no resueltas\u201d The overall objective of the ITEAS consortium, led by HISTOCELL S.L., and involving […]<\/p>\n","protected":false},"author":1,"featured_media":78801,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[17,1],"tags":[],"class_list":["post-77189","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-current-projects","category-sin-categorizar"],"_links":{"self":[{"href":"https:\/\/histocell.com\/en\/wp-json\/wp\/v2\/posts\/77189","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/histocell.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/histocell.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/histocell.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/histocell.com\/en\/wp-json\/wp\/v2\/comments?post=77189"}],"version-history":[{"count":3,"href":"https:\/\/histocell.com\/en\/wp-json\/wp\/v2\/posts\/77189\/revisions"}],"predecessor-version":[{"id":77192,"href":"https:\/\/histocell.com\/en\/wp-json\/wp\/v2\/posts\/77189\/revisions\/77192"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/histocell.com\/en\/wp-json\/wp\/v2\/media\/78801"}],"wp:attachment":[{"href":"https:\/\/histocell.com\/en\/wp-json\/wp\/v2\/media?parent=77189"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/histocell.com\/en\/wp-json\/wp\/v2\/categories?post=77189"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/histocell.com\/en\/wp-json\/wp\/v2\/tags?post=77189"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}